Greenleaf Trust Sells 2,005 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Greenleaf Trust has reduced its holdings in Thermo Fisher Scientific by 16.2%, selling 2,005 shares and now owning 10,378 shares worth approximately $4.2 million.
• Institutional investors own 89.23% of Thermo Fisher Scientific's stock, with Vanguard Group, Amundi, and others increasing their stakes significantly in the first quarter.
• The company has reported quarterly earnings of $5.36 per share, exceeding analysts’ expectations, and announced a quarterly dividend of $0.43 per share, set to be paid on October 15th.

Greenleaf Trust lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,378 shares of the medical research company's stock after selling 2,005 shares during the period. Greenleaf Trust's holdings in Thermo Fisher Scientific were worth $4,208,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the period. Amundi raised its holdings in Thermo Fisher Scientific by 5.9% during the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after buying an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after buying an additional 115,463 shares in the last quarter. Pictet Asset Management Holding SA increased its position in shares of Thermo Fisher Scientific by 7.2% during the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after acquiring an additional 193,378 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after acquiring an additional 329,974 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company's stock, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $461.95 on Tuesday. The firm's fifty day moving average price is $477.84 and its two-hundred day moving average price is $446.71. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $620.00. The firm has a market capitalization of $174.44 billion, a P/E ratio of 26.72, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TMO. UBS Group increased their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $588.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.